Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0OX5H
|
|||
| Former ID |
DIB008247
|
|||
| Drug Name |
ABT-122
|
|||
| Drug Type |
Monoclonal antibody
|
|||
| Indication | Psoriatic arthritis [ICD-11: FA21; ICD-9: 696] | Phase 2 | [1] | |
| Rheumatoid arthritis [ICD-11: FA20] | Phase 2 | [1], [2], [3] | ||
| Company |
AbbVie
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 2 | ClinicalTrials.gov (NCT02349451) A Phase 2 Study to Investigate the Safety, Tolerability and Efficacy of ABT-122 in Subjects With Active Psoriatic Arthritis Who Have an Inadequate Response to Methotrexate. U.S. National Institutes of Health. | |||
| REF 3 | ClinicalTrials.gov (NCT02433340) Phase 2, Multicenter, Open-Label Extension (OLE) Study With ABT-122 in Rheumatoid Arthritis Subjects Who Have Completed the Preceding M12-963 Study | |||
| REF 4 | DOI: 10.1136/annrheumdis-2015-eular.4042 | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.